Latest Licensing Agreements News

Canadian Phosphate Limited has bolstered its balance sheet through the sale of its pelleting plant and reported improved cash flow despite permitting setbacks in British Columbia. The company is strategically positioned to capitalize on growing North American demand for domestically sourced phosphate amid global supply disruptions.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Audeara Ltd has reported a remarkable 111% revenue increase in Q1 FY26, driven by strong growth in its technology division and key international partnerships in China and Japan. The company is advancing towards cashflow breakeven with improved cash management and expanding global reach.

Firebrick Pharma reports a $1.94 million cash reserve after a $1.4 million placement, supporting expanded Nasodine sales across Southeast Asia and the US. Board changes and increased operational costs mark a pivotal quarter for the pharmaceutical innovator.

Weebit Nano has reported a fourfold revenue increase in FY25, driven by a landmark licensing agreement with semiconductor giant onsemi and key automotive-grade qualification for its ReRAM technology.

Weebit Nano has reported a record quarter with A$7.3 million in customer receipts, securing three key product agreements and progressing critical technology milestones at leading semiconductor fabs.

archTIS has secured a A$250,000 contract to develop new features for its NC Protect product tailored to the U.S. Department of Defense’s Microsoft DoD365 environment, reinforcing its foothold in the U.S. defense sector.

Audeara Limited has landed its maiden purchase order for hearing aid technology in China, marking a pivotal step in its global expansion with production and launch planned for the final quarter of 2025.

Invion Limited has secured $0.8 million through convertible notes to repay its Lind Global Fund II LP facility and support working capital, positioning itself for potential global licensing deals of its Photosoft technology.

The U.S. FDA has lifted the clinical hold on Neurizon Therapeutics’ lead drug candidate NUZ-001, enabling its entry into a major ALS platform trial set for Q4 2025. This regulatory milestone accelerates the company’s clinical development and opens doors for broader neurodegenerative applications.

InFocus Group Holdings has launched a dedicated iGaming business unit, aiming to capitalize on the booming $95 billion online gaming industry with key contracts and digital asset integration.

Algorae Pharmaceuticals has secured an exclusive licensing agreement with Sakar Healthcare to introduce five generic oncology medicines in Australia and New Zealand, marking its first commercial foray in the region.